Association between human leukocyte antigen-DR and demylinating Guillain-Barré syndrome

References

1. ↵
   1. Yuki N,
   2. Hartung H

   (2012) Guillain–Barré Syndrome. N Engl J Med 366, 2294–2304.
2. ↵
   1. Longo DL,
   2. Fauci AS,
   3. Kasper DL,
   4. Hauser SL,
   5. Jameson JL,
   6. Loscalzo J

   1. Hauser SL,
   2. Amato AA

   (2012) Guillain Barre syndrome and other immune-mediated neuropathies. in Harrison's Principles of Internal Medicine, eds Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J (McGraw-Hill Medical, New York (NY)), 18th ed, 3473–3479.
3. 1. Kokubun N,
   2. Nishibayashi M,
   3. Uncini A,
   4. Odaka M,
   5. Hirata K,
   6. Yuki N

   (2010) Conduction block in acute motor axonal neuropathy. Brain 133, 2897–2908.
4. ↵
   1. Cheng J,
   2. Kahn DE,
   3. Wang MY

   (2011) The acute motor-sensory axonal neuropathy variant of Guillain-Barré syndrome after thoracic spine surgery. J Neurosurg Spine 15, 605–609.
5. ↵
   1. Hughes RA,
   2. Cornblath DR

   (2005) Guillain-Barré syndrome. Lancet 366, 1653–1666, Review.
6. ↵
   1. Walling AD,
   2. Dickson G

   (2013) Guillain-Barré syndrome. Am Fam Physician 87, 191–197.
7. ↵
   1. Pithadia A,
   2. Kakadia N

   (2010) Guillain-Barré syndrome (GBS). Pharmacol Rep 62, 220–232.
8. ↵
   1. Komagamine T,
   2. Yuki N

   (2006) Ganglioside mimicry as a cause of Guillain-Barré syndrome. CNS Neurol Disord Drug Targets 5, 391–400.
9. ↵
   1. Sekiguchi Y,
   2. Uncini A,
   3. Yuki N,
   4. Misawa S,
   5. Notturno F,
   6. Nasu S,
   7. et al.

   (2012) Antiganglioside antibodies are associated with axonal Guillain-Barré syndrome: a Japanese-Italian collaborative study. J Neurol Neurosurg Psychiatry 83, 23–28.
10. ↵
    1. Poropatich KO,
    2. Walker CL,
    3. Black RE

    (2010) Quantifying the association between Campylobacter infection and Guillain-Barré syndrome: a systematic review. J Health Popul Nutr 28, 545–552.
11. ↵
    1. Zautner AE,
    2. Johann C,
    3. Strubel A,
    4. Busse C,
    5. Tareen A,
    6. Masanta W,
    7. et al.

    (2014) Seroprevalence of campylobacteriosis and relevant post-infectious sequelae. Eur J Clin Microbiol Infect Dis 33, 1019–1027.
12. ↵
    1. Kishi M,
    2. Sakakibara R,
    3. Ogawa E,
    4. Tateno F,
    5. Takahashi O,
    6. Koga M

    (2011) Bilateral abducens palsy in a case of cytomegalovirus-associated Guillain-Barré syndrome. Neurol Sci 32, 1219–1222.
13. ↵
    1. An JY,
    2. Yoon B,
    3. Kim J,
    4. Song IU,
    5. Lee KS,
    6. Kim YI

    (2008) Guillain-Barré syndrome with optic neuritis and a focal lesion in the central white matter following Epstein-Barr virus infection. Intern Med 47, 1539–1542.
14. ↵
    1. Sharma MB,
    2. Chaudhry R,
    3. Tabassum I,
    4. Ahmed NH,
    5. Sahu JK,
    6. Dhawan B,
    7. et al.

    (2011) The presence of Mycoplasma pneumoniae infection and GM1 ganglioside antibodies in Guillain-Barré syndrome. J Infect Dev Ctries 5, 459–464.
15. ↵
    1. Magira EE,
    2. Papaioakim M,
    3. Nachamkin I,
    4. Asbury AK,
    5. Li CY,
    6. Ho T,
    7. et al.

    (2003) Differential distribution of HLA-DQ beta/DR beta epitopes in the 2 forms of Guillain-Barré syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): identification of DQ beta epitopes associated with susceptibility to and protection from AIDP. J Immunol 170, 3074–3080.
16. ↵
    1. Guo L,
    2. Wang W,
    3. Li C,
    4. Wang G

    (2002) [The association between HLA typing and different subtypes of Guillain Barré syndrome]. Zhonghua Nei Ke Za Zhi 41, 381–383, Chinese.
17. ↵
    1. Azuma F,
    2. Kashiwase K

    (2013) [HLA genotyping for molecular epidemiological analysis of humans]. Rinsho Byori 61, 1026–1034, Japanese.
18. ↵
    1. Geleijns K,
    2. Schreuder GM,
    3. Jacobs BC,
    4. Sintnicolaas K,
    5. van Koningsveld R,
    6. Meulstee J,
    7. et al.

    (2005) HLA class II alleles are not a general susceptibility factor in Guillain-Barré syndrome. Neurology 64, 44–49.
19. ↵
    1. Asbury AK,
    2. Cornblath DR

    (1990) Assesment of current Criteria for Guillain-Barré syndrome. Ann Neurol 27 Suppl, S21–S24.
20. ↵
    1. Hassan N,
    2. Siddiqui AR,
    3. Abbas Z,
    4. Hassan SM,
    5. Soomro GB,
    6. Mubarak M,
    7. et al.

    (2013) Clinical Profile and HLA Typing of Autoimmune Hepatitis From Pakistan. Hepat Mon 13, e13598.
21. ↵
    1. Barzegar M,
    2. Rouhi AH,
    3. Farhoudi M,
    4. Sardashti S

    (2012) A report of a probable case of familial Guillain Barre syndrome. Ann Indian Acad Neurol 15, 299–302.
22. ↵
    1. Fekih-Mrissa N,
    2. Mrad M,
    3. Riahi A,
    4. Sayeh A,
    5. Zaouali J,
    6. Gritli N

    (2014) Association of HLA-DR/DQ polymorphisms with Guillain-Barré syndrome in Tunisian patients. Clin Neurol Neurosurg 121, 19–22.
23. ↵
    1. McCombe PA,
    2. Csurhes PA,
    3. Greer JM

    (2006) Studies of HLA associations in male and female patients with Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). J Neuroimmunol 180, 172–177.
24. ↵
    1. Aquil N,
    2. Khan IA,
    3. Soomro B

    (2011) Guillain Barre syndrome in a family: a case report of four siblings. J Coll Physicians Surg Pak 21, 179–181.